Scarica l'app Stockscreener
2.43
0.82%
-0.02
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$2.45
Aprire:
$2.45
Volume 24 ore:
4,267
Relative Volume:
0.01
Capitalizzazione di mercato:
$3.76M
Reddito:
-
Utile/perdita netta:
$-36.46M
Rapporto P/E:
-1.0125
EPS:
-2.4
Flusso di cassa netto:
$-30.20M
1 W Prestazione:
+1.25%
1M Prestazione:
+66.44%
6M Prestazione:
+17.39%
1 anno Prestazione:
-81.73%
Intervallo 1D:
$2.40
$2.47
Intervallo di 1 settimana:
$2.32
$2.86
Portata 52W:
$1.3137
$14.20
Alaunos Therapeutics Inc Stock (TCRT) Company Profile
Nome
Alaunos Therapeutics Inc
Settore
Industria
Telefono
(346) 355-4099
Indirizzo
2617 BISSONNET ST, HOUSTON
Confronta TCRT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TCRT
Alaunos Therapeutics Inc
|
2.4692 | 3.76M | 0 | -36.46M | -30.20M | -2.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
501.52 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
568.61 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
629.60 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
257.13 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
247.78 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Alaunos Therapeutics Inc Stock (TCRT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-10-04 | Ripresa | Wells Fargo | Overweight |
Alaunos Therapeutics Inc Borsa (TCRT) Ultime notizie
Alaunos Therapeutics (NASDAQ:TCRT) Trading Up 2.5% – Time to Buy? - Defense World
Alaunos Therapeutics announces board member resignation - Investing.com Australia
Alaunos Therapeutics announces board member resignation By Investing.com - Investing.com Canada
Form 8-KCurrent report - ADVFN
Alaunos Therapeutics Board Opts for Equity Compensation - TipRanks
Alaunos Therapeutics announces private placement of preferred stock By Investing.com - Investing.com Canada
Alaunos Therapeutics announces private placement of preferred stock - Investing.com
Alaunos Therapeutics And 2 Other Promising Penny Stocks To Watch - simplywall.st
Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Short Interest Down 12.5% in March - Defense World
11 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Alaunos Therapeutics Inc. (TCRT) reports earnings - qz.com
Alaunos Therapeutics (NASDAQ:TCRT) Shares Down 6.5% – Here’s What Happened - Defense World
Lantheus acquires radiopharma CDMO Evergreen for up to $1bn - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Up 4% – Should You Buy? - Defense World
Update: Johnson & Johnson acquires Intra-Cellular Therapies - Pharmaceutical Technology
Light Horse emerges with $62m and Novartis partnership worth up to $1bn - Pharmaceutical Technology
Alaunos Therapeutics (NASDAQ:TCRT) Stock Price Down 0.5% – Time to Sell? - Defense World
TCRT stock touches 52-week low at $1.92 amid market challenges - Investing.com
Novartis acquires Kate Therapeutics to advance gene therapies - Pharmaceutical Technology
Alaunos Therapeutics Inc (TCRT) Quarterly 10-Q Report - Quartzy
Ziopharm: Q3 Earnings Snapshot - The Washington Post
TCRT Stock Touches 52-Week Low at $1.96 Amid Market Challenges - Investing.com Nigeria
TCRT stock touches 52-week low at $2.06 amid market challenges - Investing.com
After axing its sole clinical prospect last year, Alaunos cuts ties with Precigen - Fierce Biotech
Alaunos Therapeutics ends key agreement and updates on financial condition - Investing.com
Precigen Terminates License Agreement With Alaunos Therapeutics - MarketWatch
Genentech buys Regor’s CDK inhibitors in $850m deal - Clinical Trials Arena
VION Biosciences acquires Echelon Biosciences - Pharmaceutical Technology
Eli Lilly inaugurates R&D facility in Boston, US - Pharmaceutical Technology
Alaunos Therapeutics announces 1-for-10 reverse stock split - Investing.com
Avenzo Therapeutics secures $150m to bolster oncology pipeline - Pharmaceutical Technology
Gilead concludes acquisition of CymaBay Therapeutics for $4.3bn - Pharmaceutical Technology
Alaunos Therapeutics Announces 1-for-15 Reverse Stock Split - TipRanks
Kyowa Kirin acquires Orchard Therapeutics for $477.6m - Pharmaceutical Technology
NAYA buys gene therapy company Florida Biotech for $20m - Clinical Trials Arena
Genentech signs nanoparticle deal worth up to $644m with GenEdit - Pharmaceutical Technology
BridGene and Galapagos partner for oncology drugs discovery - Pharmaceutical Technology
Novartis allies with Voyager to develop gene therapies in $1.3bn deal - Pharmaceutical Technology
Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today? - MSN
Syncona to buy biotechnology company Freeline Therapeutics - Pharmaceutical Technology
Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives - Yahoo Finance
Ascidian Therapeutics raises $40m to advance drug development - Pharmaceutical Technology
AstraZeneca and Cellectis partner to advance cell and gene therapies - Pharmaceutical Technology
How gene therapies can transform sickle cell disease treatment - Pharmaceutical Technology
StockWatch: Illumina Results Leave Investors, Analysts Anxious - Genetic Engineering and Biotechnology News
Alaunos (TCRT) to Wind Down Sole Clinical Study, Stock Dips 65% - Nasdaq
Houston biotech winds down sole clinical-stage trial, cuts 60% of staff - Fierce Biotech
Houston BioTech Donation Enriches UH Program - University of Houston
15 Biotech Stocks Wall Street Analysts Say Are Too Cheap - Barron's
Hopewell Therapeutics raises funds for genomic medicines development - Pharmaceutical Technology
Alaunos Therapeutics Inc Azioni (TCRT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.36%
0.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):